CAMEO+ eventCORPORATE2026-04-14馃嚭馃嚫
Eli Lilly acquires CrossBridge Bio to boost dual-payload antibody R&D
source: Eli Lilly and Company -> target: CrossBridge Bio, Inc.
On 2026-04-14, Eli Lilly and Company reached an agreement to acquire Houston-based CrossBridge Bio, Inc. for up to $300 million, according to the article. The deal is intended to boost Lilly鈥檚 dual-payload antibody-drug conjugate research and development capabilities.
0.15Significance1.0Magnitude0.2Systemic0.3Market1Articles
Location
IndianapolisIndianaNorth AmericaUnited StatesNorth America39.768, -86.158
Story Links